Hepatitis C Virus | Current Treatment | EU5 | 2017
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA authorizations of Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), combined with Bristol-Myers Squibb’s Daklinza (daclatasvir) and AbbVie’s Viekirax +/- Exviera (ombitasvir/paritaprevir/ritonavir +/- dasabuvir), have ushered in the era of IFN-free therapy for chronic HCV and completely reshaped the HCV therapeutic market. Recent EMA approvals of Gilead’s Epclusa (sofosbuvir/velpatasvir) and Merck & Co’s Zepatier (elbasvir/grazoprevir) provide additional IFN-free options for EU5 HCV patients. Taken together, currently approved regimens provide efficacious IFN-free options for most HCV genotypes in the EU5. This research focuses on current and anticipated use of HCV regimens, including IFN-free and remaining IFN-based regimens, by capturing patient-share data, current prescribing trends, and anticipated changes in prescribing and treatment. We also evaluate physician-perceived drivers and obstacles to the uptake of key brands.
Questions Answered in This Report:
What factors influence physicians’ treatment and management of chronic HCV infections?
What are the major drug attributes driving physicians to prescribe certain brands?
What obstacles prevent physician prescribing of key HCV therapies?
How do physicians anticipate their prescribing of different therapies to change in the next six months?
Scope:
Markets covered: France, Germany, Italy, Spain, and United Kingdom
Methodology: Survey of 89 gastroenterologists and 162 hepatologists; approximately 50 respondents per EU5 country
Key drugs covered: Incivo, Victrelis, Sovaldi, Olysio, Daklinza, Harvoni, Viekirax + Exviera, Zepatier, Epclusa, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir
Key companies mentioned: AbbVie, Bristol-Myers Squibb, Gilead, Merck & Co., Janssen, Johnson & Johnson, Roche
